Press releases

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2019. Learn how to tune in.

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.

Vertiflex acquisition adds the only FDA-approved, commercially available, minimally invasive interspinous spacer to Boston Scientific’s chronic pain portfolio.

WATCHMAN device findings could expand number of non-valvular atrial fibrillation (AFib) patients who can receive alternative treatment to lifelong use of blood thinners.

Boston Scientific (BSX) will participate in an upcoming investor conference in May 2019. A live webcast and replay will be available.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies.

Boston Scientific will participate in the upcoming healthcare conference in May 2019. A live webcast and replay will be available.

Results includes data about Boston Scientific S-ICD, POLARx cryoablation catheter, WATCHMAN device and LUX-Dx insertable cardiac monitor.

Boston Scientific will participate in the upcoming investor healthcare conference in May 2019. A live webcast and replay will be available.